New treatment approaches in CLL: Challenges and opportunities in the elderly

详细信息    查看全文

• 作者：Barbara Eichhorst^a ; ^{barbara.eichhorst@uk-koeln.de" class="auth_mail" title="E-mail the corresponding author} ; Michael Hallek^a ; ^b ; Valentin Goede^a ; ^c
• 关键词：Chronic lymphocytic leukemia ; Chemoimmunotherapy ; Kinase inhibitors ; BCL2 inhibitor
• 刊名：Journal of Geriatric Oncology
• 出版年：2016
• 出版时间：September 2016
• 年：2016
• 卷：7
• 期：5
• 页码：375-382
• 全文大小：284 K

文摘

The majority of patients with chronic lymphocytic leukemia (CLL) are over 70 years old. These patients vary in their vulnerability toward treatment efforts. Heterogeneity in fitness of older patients with CLL is mainly determined by individual differences in physiological aging and pathological conditions such as comorbidities and geriatric syndromes. Various options exist to treat older patients with CLL outside and inside clinical trials. Among these are new treatment approaches, including chemoimmunotherapy with engineered CD20 antibodies (e.g., obinutuzumab), single agent therapy with kinase inhibitors (e.g., ibrutinib, idelalisib), other targeted drug therapy (e.g., venetoclax, lenalidomide), and combinations of these novel compounds. Treatment recommendations for older patients take patient-related as well as disease-related risk factors into consideration. Emerging new treatment approaches in older patients offer novel opportunities, but also novel challenges which are discussed in this review.